1. Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl

   • Hao Sun
   • Kristen A. Cardinal
   • Anthony J. Lee

   Original Article 18 April 2022 Pages: 737 - 750

   

2. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer

   • Khushboo A. Gandhi
   • Amit Joshi
   • Vikram Gota

   Original Article 19 April 2022 Pages: 751 - 759

   

3. RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

   • Mototsugu Oya
   • Shuichi Kaneko
   • Yutaka Okayama

   Original Article Open access 20 April 2022 Pages: 761 - 772

   

4. An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells

   • Oula C. Mansour
   • Abraham Nudelman
   • Benny J. Evison

   Original Article 23 April 2022 Pages: 773 - 784

   

5. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

   • Marit A. C. Vermunt
   • Merel van Nuland
   • Andries M. Bergman

   Original Article Open access 25 April 2022 Pages: 785 - 793

   

6. Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice

   • Brian F. Kiesel
   • Joshua J. Deppas
   • Jan H. Beumer

   Original Article 04 May 2022 Pages: 795 - 807

   

7. The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study

   • Lara Massai
   • Luigi Messori
   • Francesca Magherini

   Original Article Open access 11 May 2022 Pages: 809 - 823

   

8. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma

   • Weiping Liu
   • Lingyan Ping
   • Jun Zhu

   Clinical Trial Report 23 March 2022 Pages: 825 - 831

   

9. Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib

   • Hiroaki Ikesue
   • Kenta Yamaoka
   • Tohru Hashida

   Short Communication Open access 07 March 2022 Pages: 833 - 838

   

10. Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

    • Jennifer E. Hibma
    • Melissa O’Gorman
    • Yazdi K. Pithavala

    Correction Open access 18 March 2022 Pages: 839 - 839

11. Editorial Expression of Concern for: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis

    • Nidhi Nigam
    • Jasmine George
    • Yogeshwer Shukla

    Editorial Expression of Concern 05 April 2022 Pages: 841 - 841

12. Retraction Note to: MicroRNA‑30c‑regulated HDAC9 mediates chemoresistance of breast cancer

    • Zhongxing Liang
    • Amber Feng
    • Hyunsuk Shim

    Retraction Note 24 February 2022 Pages: 843 - 843